Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Eylea"

34 News Found

Complement Therapeutics raises €5 million seed financing
News | February 23, 2022

Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
News | January 28, 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio

U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
Drug Approval | September 21, 2021

U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar

It becomes the first ophthalmology biosimilar to gain FDA approval in the United States

Zydus and Bayer announce extension of their JV
News | June 21, 2021

Zydus and Bayer announce extension of their JV

Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Zealand Pharma’s petrelintide delivers double-digit weight loss in next-gen obesity treatment

Teva study shows Huntington’s disease treatment improves life for patients & caregivers

Oval & Merck Specialities sign strategic pact to expand access to advanced IVF care in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging